Prognostic implications of baseline anaemia and changes in haemoglobin concentrations with amphotericin B therapy for cryptococcal meningitis

HIV Medicine

Volumn 18, Issue 1, 2017, Pages 13-20

  Tugume, L ^a   Morawski, B M ^b,c   Abassi, M ^a,b   Bahr, N C ^a,b   Kiggundu, R ^a   Nabeta, H W ^a   Hullsiek, K H ^c   Taseera, K ^d   Musubire, A K ^a,b   Schutz, C ^e   Muzoora, C ^d   Williams, D A ^a,b   Rolfes, M A ^f   Meintjes, G ^e,g   Rhein, J ^a,b   Meya, D B ^a,b   Boulware, D R ^b  

^a MAKERERE UNIVERSITY   (Uganda)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

amphotericin B; anaemia; cryptococcal meningitis; HIV

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FLUCONAZOLE; HEMOGLOBIN; SERTRALINE; AMPHOTERICIN B; ANTIFUNGAL AGENT;

ADULT; ANEMIA; ANTIFUNGAL THERAPY; ANTIRETROVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; ADOLESCENT; COMPLICATION; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; PATHOLOGY; SOUTH AFRICA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UGANDA; YOUNG ADULT;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANEMIA; ANTIFUNGAL AGENTS; FEMALE; HEMOGLOBINS; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; SOUTH AFRICA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UGANDA; YOUNG ADULT;

EID: 84964621568     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12387     Document Type: Article

References (27)

1. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998; 91: 301–308.
2. Mocroft A, Kirk O, Barton SE et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS 1999; 13: 943–950.
3. Berhane K, Karim R, Cohen MH et al. Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women - Women's interagency HIV study. J Acquir Immune Defic Syndr 2004; 37: 1245–1252.
4. O'Brien ME, Kupka R, Msamanga GI, Saathoff E, Hunter DJ, Fawzi WW. Anemia is an independent predictor of mortality and immunologic progression of disease among women with HIV in Tanzania. J Acquir Immune Defic Syndr 2005; 40: 219–225.
5. Johannessen A, Naman E, Ngowi BJ et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis 2008; 8: 52.
6. Masaisa F, Gahutu JB, Mukiibi J, Delanghe J, Philippe J. Anemia in human immunodeficiency virus-infected and uninfected women in Rwanda. Am J Trop Med Hyg 2011; 84: 456–460.
7. Parkes-Ratanshi R, Katende D, Levin J et al. Development of severe anemia and changes in hemoglobin in a cohort of HIV-infected Ugandan adults receiving zidovudine-, stavudine-, and tenofovir-containing antiretroviral regimens. J Int Assoc Provid AIDS Care 2015; 14: 455–462.
8. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis 2004; 38: 1454–1463.
9. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23: 525–530.
10. Liechty CA, Solberg P, Were W et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007; 12: 929–935.
11. French N, Gray K, Watera C et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16: 1031–1038.
12. van der Horst CM, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997; 337: 15–21.
13. Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS ONE 2008; 3: e2870.
14. Brouwer AE, Rajanuwong A, Chierakul W et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363: 1764–1767.
15. Day JN, Chau TT, Wolbers M et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013; 368: 1291–1302.
16. Bicanic T, Bottomley C, Loyse A et al. Toxicity of amphotericin B deoxycholate-based induction therapy in patients with HIV-associated cryptococcal meningitis. Antimicrob Agents Chemother 2015; 59: 7224–7231.
17. Joly V, Aubry P, Ndayiragide A et al. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1996; 23: 556–562.
18. Lin AC, Goldwasser E, Bernard EM, Chapman SW. Amphotericin B blunts erythropoietin response to anemia. J Infect Dis 1990; 161: 348–351.
19. MacGregor RR, Bennett JE, Erslev AJ. Erythropoietin concentration in amphotericin B-induced anemia. Antimicrob Agents Chemother 1978; 14: 270–273.
20. Brandriss MW, Wolff SM, Moores R, Stohlman F Jr. Anemia Induced by Amphotericin B. JAMA 1964; 189: 663–666.
21. Jarvis JN, Bicanic T, Loyse A et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis 2014; 58: 736–745.
22. Boulware DR, Meya DB, Muzoora C et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 2014; 370: 2487–2498.
23. National Institutes of Health. National Institute of Allergy and Infectious Disease, Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2009.
24. Bicanic T, Wood R, Meintjes G et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008; 47: 123–130.
25. Muzoora CK, Kabanda T, Ortu G et al. Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. J Infect 2012; 64: 76–81.
26. Jackson AT, Nussbaum JC, Phulusa J et al. A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS 2012; 26: 1363–1370.
27. Lundgren JD, Mocroft A. Anemia and survival in human immunodeficiency virus. Clin Infect Dis 2003; 37 (Suppl 4): S297–S303.